617 related articles for article (PubMed ID: 15994154)
1. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
4. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
5. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
7. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
8. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
9. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
[TBL] [Abstract][Full Text] [Related]
11. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
12. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
15. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
16. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
Kimmick GG; Peterson BL; Kornblith AB; Mandelblatt J; Johnson JL; Wheeler J; Heinze R; Cohen HJ; Muss HB
J Clin Oncol; 2005 Apr; 23(10):2201-7. PubMed ID: 15800312
[TBL] [Abstract][Full Text] [Related]
17. Five-year change in statistical designs of phase II trials published in leading cancer journals.
Thezenas S; Duffour J; Culine S; Kramar A
Eur J Cancer; 2004 May; 40(8):1244-9. PubMed ID: 15110889
[TBL] [Abstract][Full Text] [Related]
18. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
19. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
20. Designs for efficient clinical trials.
Simon R
Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
